Anti-interleukin-6 therapies for Covid-19: A systematic review, critical appraisal and meta-analysis | Zendy

Kameshwar Prasad | Zendy; Arunmozhimaran Elavarasi | Zendy; RanjitKumar Sahoo | Zendy; Tulika Seth | Zendy; S. Shalimar | Zendy; Karan Madan | Zendy; Neeraj Nischal | Zendy; Manish Soneja | Zendy; Atul Sharma | Zendy; Pramod Kumar Garg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-interleukin-6 therapies for Covid-19: A systematic review, critical appraisal and meta-analysis

Author(s) -

Kameshwar Prasad,

Arunmozhimaran Elavarasi,

RanjitKumar Sahoo,

Tulika Seth,

S. Shalimar,

Karan Madan,

Neeraj Nischal,

Manish Soneja,

Atul Sharma,

Pramod Kumar Garg

Publication year - 2020

Publication title -

the national medical journal of india

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.2

H-Index - 41

ISSN - 0970-258X

DOI - 10.4103/0970-258x.288119

Subject(s) - critical appraisal , meta analysis , covid-19 , systematic review , medicine , medline , psychology , virology , alternative medicine , biology , pathology , disease , outbreak , infectious disease (medical specialty) , biochemistry

. Coronavirus disease 2019 (Covid-19) has emerged as a pandemic by end-January 2020. Of the infected patients, 10%-15% may develop severe or critical illness. So far, no definite treatment is available for Covid-19. Cytokine release syndrome may underlie the pathogenesis of severe and critical disease. Anti-interleukin (IL)-6 therapies are being tried to improve clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research